Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768351 | 1.00 | PARP1 (0.39) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| Hydrochloric Acid SCHEMBL1027120 | 0.98 | PARP1 (0.38) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL153211 | 0.79 | AHR (0.45) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL30079633 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL21893243 | 0.76 | ALOX15 (0.40) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL31394015 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL30748780 | 0.76 | PARP1 (0.42) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL14758337 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL6342164 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 | |
| SCHEMBL9910093 | 0.76 | MAPT (0.36) | PARP1MAPTNPSR1RXFP1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1979358-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| EP-0994862-B1 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| CN-1087294-C | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2002-07-10 | — | — | CN | disclosed |
| US-6316450-B1 | PIPERAZINE COMPOUNDS FOR TREATING DEPRESSION AND ANXIETY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-13 | — | — | US | disclosed |
| CN-1261883-A | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2000-08-02 | — | — | CN | disclosed |
| EP-0994862-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999002502-A2 | SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BEECHAM PLC (GB) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018128-A1 | Compounds | CNR2, CNR1, TRPV1 | PARP1 1564/4885MAPT 1679/4885NPSR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.